SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma - Quaterly Results

04 Feb 2026 Evaluate
The Revenue for the quarter ended  December 2025 of Rs. 26326.80 millions grew by 8.29 % from Rs. 24311.50 millions.Profit saw a slight increase of 10.86%to Rs. 4494.70  millions from Rs. 4054.50 millions.OP of the company witnessed a marginal growth to 8347.70 millions from 8138.40 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 26326.80 24311.50 8.29 77828.20 73879.50 5.34 94978.00 86292.50 10.07
Other Income 565.20 703.90 -19.70 1984.10 2739.10 -27.56 4932.10 2705.00 82.33
PBIDT 8347.70 8138.40 2.57 23429.20 23568.90 -0.59 30557.60 25367.90 20.46
Interest 1383.70 2026.20 -31.71 4322.70 2118.60 104.04 3717.60 163.30 2176.55
PBDT 6129.80 6112.20 0.29 18272.30 21450.30 -14.82 26840.00 25204.60 6.49
Depreciation 1076.90 983.20 9.53 3036.50 2799.80 8.45 3780.10 3352.60 12.75
PBT 5052.90 5129.00 -1.48 15235.80 18650.50 -18.31 23059.90 21852.00 5.53
TAX 558.20 1074.50 -48.05 2024.50 3698.30 -45.26 4217.40 4125.70 2.22
Deferred Tax -657.40 -284.00 131.48 -1087.90 -70.30 1447.51 -481.90 12.40 -3986.29
PAT 4494.70 4054.50 10.86 13211.30 14952.20 -11.64 18842.50 17726.30 6.30
Equity 412.80 412.60 0.05 412.80 412.60 0.05 412.60 400.60 3.00
PBIDTM(%) 31.71 33.48 -5.28 30.10 31.90 -5.64 32.17 29.40 9.44

Mankind Pharma Share Price

2078.75 24.65 (1.20%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×